FULC Fundamental Analysis - FULCRUM THERAPEUTICS INC

Name: FULCRUM THERAPEUTICS INC (FULC) Stock
Brand: FULCRUM THERAPEUTICS INC
Rating: 7.5 (3 reviews)

Fundamental Rating

Overall FULC gets a fundamental rating of 4 out of 10. We evaluated FULC against 192 industry peers in the Pharmaceuticals industry. While FULC has a great health rating, there are worries on its profitability. FULC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FULC has reported negative net income.

FULC had a negative operating cash flow in the past year.

FULC had negative earnings in each of the past 5 years.

FULC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -4.25%, FULC is in the better half of the industry, outperforming 72.40% of the companies in the same industry.

FULC has a Return On Equity of -4.54%. This is in the better half of the industry: FULC outperforms 77.08% of its industry peers.

		Industry Rank	Sector Rank
ROA	-4.25%
ROE	-4.54%
ROIC	N/A

ROA(3y)-29.99%

ROA(5y)-35.8%

ROE(3y)-33.54%

ROE(5y)-42.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.

FULC has less shares outstanding than it did 1 year ago.

FULC has more shares outstanding than it did 5 years ago.

There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

FULC has an Altman-Z score of 20.22. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of FULC (20.22) is better than 90.63% of its industry peers.

FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	20.22

ROIC/WACCN/A

WACC8.71%

2.3 Liquidity

FULC has a Current Ratio of 24.42. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.

FULC has a better Current ratio (24.42) than 94.27% of its industry peers.

FULC has a Quick Ratio of 24.42. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.

FULC has a Quick ratio of 24.42. This is amongst the best in the industry. FULC outperforms 94.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	24.42
Quick Ratio	24.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FULC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -248.57%.

The Revenue has grown by 2752.05% in the past year. This is a very strong growth!

Measured over the past years, FULC shows a very strong growth in Revenue. The Revenue has been growing by 61.03% on average per year.

EPS 1Y (TTM)-248.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-132.18%

Revenue 1Y (TTM)2752.05%

Revenue growth 3Y61.03%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

FULC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.59% yearly.

FULC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -9.72% yearly.

EPS Next Y-430.28%

EPS Next 2Y-135.14%

EPS Next 3Y-70.76%

EPS Next 5Y-21.59%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FULC. In the last year negative earnings were reported.

Also next year FULC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

FULC's earnings are expected to decrease with -70.76% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-135.14%

EPS Next 3Y-70.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FULC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (10/29/2025, 5:20:00 PM)

After market: 9.36 0 (0%)

9.36

-0.64 (-6.4%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)07-29 2025-07-29/bmo

Earnings (Next)10-29 2025-10-29/bmo

Inst Owners101.13%

Inst Owner Change-0.03%

Ins Owners0.63%

Ins Owner Change-0.01%

Market Cap506.28M

Revenue(TTM)80.00M

Net Income(TTM)-9725000

Analysts80

Price Target11.29 (20.62%)

Short Float %6.67%

Short Ratio7.81

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)5.99%

Min EPS beat(2)5.34%

Max EPS beat(2)6.63%

EPS beat(4)4

Avg EPS beat(4)8.2%

Min EPS beat(4)5.34%

Max EPS beat(4)15.39%

EPS beat(8)8

Avg EPS beat(8)872.5%

EPS beat(12)11

Avg EPS beat(12)585.52%

EPS beat(16)13

Avg EPS beat(16)439.89%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)35.96%

EPS NQ rev (1m)0%

EPS NQ rev (3m)1.61%

EPS NY rev (1m)0%

EPS NY rev (3m)2.12%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.33
P/FCF	N/A
P/OCF	N/A
P/B	2.36
P/tB	2.36
EV/EBITDA	N/A

EPS(TTM)-1.22

EYN/A

EPS(NY)-1.22

Fwd EYN/A

FCF(TTM)-1.21

FCFYN/A

OCF(TTM)-1.2

OCFYN/A

SpS1.48

BVpS3.96

TBVpS3.96

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.25%
ROE	-4.54%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-29.99%

ROA(5y)-35.8%

ROE(3y)-33.54%

ROE(5y)-42.65%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	21.95%
Cap/Sales	0.39%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	24.42
Quick Ratio	24.42
Altman-Z	20.22

F-Score5

WACC8.71%

ROIC/WACCN/A

Cap/Depr(3y)40.72%

Cap/Depr(5y)49.27%

Cap/Sales(3y)16.46%

Cap/Sales(5y)14.7%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-248.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-132.18%

EPS Next Y-430.28%

EPS Next 2Y-135.14%

EPS Next 3Y-70.76%

EPS Next 5Y-21.59%

Revenue 1Y (TTM)2752.05%

Revenue growth 3Y61.03%

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-9.72%

EBIT growth 1Y82.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-223.85%

EBIT Next 3Y-40.78%

EBIT Next 5YN/A

FCF growth 1Y30.05%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y29.81%

OCF growth 3YN/A

OCF growth 5YN/A

FULCRUM THERAPEUTICS INC / FULC FAQ

What is the fundamental rating for FULC stock?

ChartMill assigns a fundamental rating of 4 / 10 to FULC.

Can you provide the valuation status for FULCRUM THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FULCRUM THERAPEUTICS INC (FULC). This can be considered as Overvalued.

Can you provide the profitability details for FULCRUM THERAPEUTICS INC?

FULCRUM THERAPEUTICS INC (FULC) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for FULC stock?

The Earnings per Share (EPS) of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -430.28% in the next year.

FULCRUM THERAPEUTICS INC (FULC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

FULCRUM THERAPEUTICS INC / FULC FAQ

What is the fundamental rating for FULC stock?

Can you provide the valuation status for FULCRUM THERAPEUTICS INC?

Can you provide the profitability details for FULCRUM THERAPEUTICS INC?

Can you provide the expected EPS growth for FULC stock?